Attie, Kenneth M.

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Platzbecker, U., Germing, U., Götze, K. S., Kiewe, P., Mayer, K., Chromik, J., Radsak, M., Wolff, T., Zhang, X., Laadem, A., et al. (2017) · The Lancet Oncology

Acute Myeloid Leukemia ResearchErythropoietin and Anemia Treatment

Cited by 292

Growth hormone therapy of Turner's syndrome: beneficial effect on adult height

Rosenfeld, R. G., Attie, K. M., Frane, J., Brasel, A., Burstein, S., Cara, J. F., Chernausek, S., Gotlin, R. W., Kuntze, J., Lippe, B. M., et al. (1998) · The Journal of Pediatrics

Growth Hormone and Insulin-like Growth FactorsGenetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities

Cited by 265

Treatment of Glucocorticoid-Induced Growth Suppression with Growth Hormone

Allen, D. B., Julius, J. R., Breen, T. J., & Attie, K. M. (1998) · The Journal of Clinical Endocrinology & Metabolism

Growth Hormone and Insulin-like Growth FactorsPituitary Gland Disorders and Treatments

Cited by 153

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia

Piga, A., Perrotta, S., Gamberini, M. R., Voskaridou, E., Melpignano, A., Filosa, A., Caruso, V., Pietrangelo, A., Longo, F., Tartaglione, I., et al. (2019) · Blood

Hemoglobinopathies and Related DisordersIron Metabolism and Disorders

Cited by 119